Cardiology – Acute Myocardial Infarction (AMI)
Cesca is developing a proprietary, point-of-care autologous stem cell-based therapy intended as an adjunct treatment for patients who have suffered an acute ST-elevated myocardial infarction (“STEMI”), the most serious type of heart attack. Such treatments are aimed at minimizing the adverse remodeling of the heart post-STEMI.
TotipotentRX Cellular Medicine Inc (BVI).
185 Technology Dr Suite 150, Irvine California 92618
Tel : 1 (888) 379-2670